JP2022036971A5 - - Google Patents

Download PDF

Info

Publication number
JP2022036971A5
JP2022036971A5 JP2021187608A JP2021187608A JP2022036971A5 JP 2022036971 A5 JP2022036971 A5 JP 2022036971A5 JP 2021187608 A JP2021187608 A JP 2021187608A JP 2021187608 A JP2021187608 A JP 2021187608A JP 2022036971 A5 JP2022036971 A5 JP 2022036971A5
Authority
JP
Japan
Prior art keywords
flow
resin
mode
hic
chromatography step
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021187608A
Other languages
English (en)
Japanese (ja)
Other versions
JP7489953B2 (ja
JP2022036971A (ja
Filing date
Publication date
Priority claimed from JP2016542814A external-priority patent/JP6751344B2/ja
Application filed filed Critical
Publication of JP2022036971A publication Critical patent/JP2022036971A/ja
Publication of JP2022036971A5 publication Critical patent/JP2022036971A5/ja
Priority to JP2024007221A priority Critical patent/JP2024059617A/ja
Application granted granted Critical
Publication of JP7489953B2 publication Critical patent/JP7489953B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021187608A 2013-09-13 2021-11-18 精製された組み換えポリペプチドを含む方法及び組成物 Active JP7489953B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024007221A JP2024059617A (ja) 2013-09-13 2024-01-22 精製された組み換えポリペプチドを含む方法及び組成物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361877517P 2013-09-13 2013-09-13
US61/877,517 2013-09-13
JP2016542814A JP6751344B2 (ja) 2013-09-13 2014-09-12 精製された組み換えポリペプチドを含む方法及び組成物
JP2019095933A JP6982027B2 (ja) 2013-09-13 2019-05-22 精製された組み換えポリペプチドを含む方法及び組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019095933A Division JP6982027B2 (ja) 2013-09-13 2019-05-22 精製された組み換えポリペプチドを含む方法及び組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024007221A Division JP2024059617A (ja) 2013-09-13 2024-01-22 精製された組み換えポリペプチドを含む方法及び組成物

Publications (3)

Publication Number Publication Date
JP2022036971A JP2022036971A (ja) 2022-03-08
JP2022036971A5 true JP2022036971A5 (enExample) 2022-05-11
JP7489953B2 JP7489953B2 (ja) 2024-05-24

Family

ID=52666315

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016542814A Active JP6751344B2 (ja) 2013-09-13 2014-09-12 精製された組み換えポリペプチドを含む方法及び組成物
JP2019095933A Active JP6982027B2 (ja) 2013-09-13 2019-05-22 精製された組み換えポリペプチドを含む方法及び組成物
JP2021187608A Active JP7489953B2 (ja) 2013-09-13 2021-11-18 精製された組み換えポリペプチドを含む方法及び組成物
JP2024007221A Pending JP2024059617A (ja) 2013-09-13 2024-01-22 精製された組み換えポリペプチドを含む方法及び組成物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2016542814A Active JP6751344B2 (ja) 2013-09-13 2014-09-12 精製された組み換えポリペプチドを含む方法及び組成物
JP2019095933A Active JP6982027B2 (ja) 2013-09-13 2019-05-22 精製された組み換えポリペプチドを含む方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024007221A Pending JP2024059617A (ja) 2013-09-13 2024-01-22 精製された組み換えポリペプチドを含む方法及び組成物

Country Status (18)

Country Link
US (8) US9920120B2 (enExample)
EP (3) EP3683232A1 (enExample)
JP (4) JP6751344B2 (enExample)
KR (2) KR102571391B1 (enExample)
CN (2) CN105722532A (enExample)
AR (3) AR097651A1 (enExample)
AU (2) AU2014318615B2 (enExample)
BR (1) BR112016004413A2 (enExample)
CA (2) CA3184564A1 (enExample)
HK (1) HK1225988A1 (enExample)
IL (2) IL244149B2 (enExample)
MX (3) MX382393B (enExample)
MY (2) MY176026A (enExample)
NZ (3) NZ718144A (enExample)
RU (1) RU2671481C2 (enExample)
SG (2) SG10201802525QA (enExample)
WO (1) WO2015038888A1 (enExample)
ZA (4) ZA201601965B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3680000B1 (en) 2013-03-15 2024-03-13 GlaxoSmithKline Intellectual Property Development Limited Methods for purifying antibodies
JP6592426B2 (ja) 2013-03-15 2019-10-16 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. 無塩条件下で疎水性相互作用クロマトグラフィーを使用するタンパク質精製
IL244149B2 (en) * 2013-09-13 2025-09-01 Genentech Inc Methods and compositions containing purified recombinant polypeptides
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
TW201702380A (zh) 2015-02-27 2017-01-16 再生元醫藥公司 宿主細胞蛋白質修飾
EP3337819B1 (en) * 2015-08-20 2024-02-21 F. Hoffmann-La Roche AG Method of purifying for producing recombinant polypeptides using fkpa
CN107835819A (zh) * 2015-08-21 2018-03-23 豪夫迈·罗氏有限公司 在亲和层析中减少宿主细胞蛋白的方法
AU2016312909B2 (en) * 2015-08-21 2022-12-08 F. Hoffmann-La Roche Ag Method for the reduction of host cell proteins in affinity chromatography
IL290358B2 (en) 2016-04-14 2024-03-01 Lonza Ag Preparations and methods for detecting host cell proteins
KR20240052871A (ko) 2016-04-27 2024-04-23 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
ES2994244T3 (en) * 2016-07-25 2025-01-21 Cephalon Llc Affinity chromatography wash buffer
IL264631B2 (en) 2016-08-16 2024-05-01 Regeneron Pharma A method for quantifying individual antibodies from a mixture
EP4389757A3 (en) 2016-09-07 2025-01-01 GlaxoSmithKline Intellectual Property Development Limited Methods for purifying antibodies
CA3037264A1 (en) * 2016-10-06 2018-04-12 Glaxosmithkline Intellectual Property Development Limited Antibodies with reduced binding to process impurities
EP4071469B1 (en) 2016-10-25 2025-04-09 Regeneron Pharmaceuticals, Inc. Methods for chromatography data analysis
RS63533B1 (sr) 2016-12-23 2022-09-30 Serum Institute Of India Pvt Ltd Postupci za povećanje produktivnosti antitela u kulturi sisarskih ćelija i smanjenje agregacije tokom nishodne obrade, postupci formulacije i rezultujuće stabilne formulacije antitela
WO2019060062A1 (en) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals Inc. METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREFROM
TW202003555A (zh) * 2018-03-07 2020-01-16 英商葛蘭素史克智慧財產發展有限公司 用於純化重組多肽之方法
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
WO2020023566A1 (en) * 2018-07-25 2020-01-30 Merck Sharp & Dohme Corp. Methods of separating host cell lipases from a production protein in chromatographic processes
US20220098235A1 (en) 2019-01-23 2022-03-31 Daiichi Sankyo Company, Limited Methods for purifying antibodies comprising of a process by using activated carbon materials
WO2020157749A1 (en) * 2019-01-29 2020-08-06 Bnai Zion Medical Center Anti il-17 antibody for use in treating chronic spontaneous urticaria
BR112021020378A2 (pt) * 2019-04-17 2021-12-07 Regeneron Pharma Identificação de proteínas de célula hospedeira
EA202193198A1 (ru) * 2019-05-21 2022-02-24 Ридженерон Фармасьютикалз, Инк. Способы идентификации и количественного определения белка клетки-хозяина
US20220314142A1 (en) * 2019-07-01 2022-10-06 Pfizer Inc. Improvements to wash solutions for protein a chromatography in an antibody purification process
EP4038083A1 (en) * 2019-10-04 2022-08-10 Merck Patent GmbH Purification of proteins and viral inactivation
EP4096802A4 (en) * 2020-01-29 2024-07-03 Merck Sharp & Dohme LLC METHOD FOR SEPARATION OF HOST CELL LIPASES FROM ANTI-LAG3 ANTIBODY PRODUCTION
AU2022268912A1 (en) * 2021-05-03 2023-11-23 Agilent Technologies, Inc. Chimeric immunogens and methods for making polyclonal antibodies against specific epitopes
EP4518839A2 (en) * 2022-05-02 2025-03-12 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity
WO2023245187A2 (en) 2022-06-17 2023-12-21 Apogee Biologics, Inc. Antibodies that bind interleukin 13 and methods of use
CN120641127A (zh) * 2022-12-19 2025-09-12 伊莱利利公司 减少蛋白纯化中污染物的方法
AR133647A1 (es) 2023-08-25 2025-10-22 Proteologix Us Inc Constructos de anticuerpos multiespecíficos anti-il-13 y usos de los mismos
CN117169518B (zh) * 2023-11-03 2024-01-19 赛德特(北京)生物工程有限公司 T淋巴细胞制剂中的cd3抗体残留物的检测方法和试剂盒
WO2025137344A1 (en) 2023-12-20 2025-06-26 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods

Family Cites Families (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2031216A1 (de) 1969-06-19 1971-01-14 Citizen Watch Co Ltd , Tokio Tag und Datum Stellvorrichtung fur Uhren mit Kalender
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3422247A1 (de) 1984-06-15 1985-12-19 Pfeifer & Langen, 5000 Köln Gluco-oligosaccharid-gemisch und verfahren zu seiner herstellung
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
WO1989004838A1 (en) 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US5359037A (en) 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US4847745A (en) 1988-11-16 1989-07-11 Sundstrand Corp. Three phase inverter power supply with balancing transformer
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5011778A (en) 1989-05-23 1991-04-30 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2085983T3 (es) 1989-12-20 1996-06-16 Schering Corp Antagonistas de anticuerpos de la interleuquina-4 humana.
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
JP2865423B2 (ja) 1991-03-29 1999-03-08 エルフ・サノフィ サイトカイン型の活性を有するタンパク質、およびこのタンパク質をコード化する組換えdna、形質転換細胞および微生物
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5994514A (en) 1991-08-14 1999-11-30 Genentech, Inc. Immunoglobulin variants
US6329509B1 (en) 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
US5965709A (en) 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
JPH08500962A (ja) 1992-02-06 1996-02-06 クリエイティブ バイオモレキュルズ,インコーポレイテッド 癌マーカー用生物合成結合蛋白質
WO1993015766A1 (en) 1992-02-10 1993-08-19 Seragen, Inc. Desensitization to specific allergens
EP0626012B1 (en) 1992-02-11 2003-07-09 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
AU680816B2 (en) 1992-05-15 1997-08-14 Quest International B.V. Cloning and expression of DNA encoding a ripening form of a polypeptide having phamnogalacturonase activity
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
EP0656947A1 (en) 1992-08-21 1995-06-14 Schering Corporation Human interleukin-13
US5596072A (en) 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
DK0866130T3 (da) 1993-05-17 2010-10-04 Genentech Inc CHO-celle-sialidase ved rekombinant DNA-teknologi
CN100341896C (zh) 1993-09-02 2007-10-10 达特茅斯学院理事 抗gp39抗体及其应用
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US6037453A (en) 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US6518061B1 (en) 1995-03-15 2003-02-11 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
ES2334408T3 (es) 1995-10-23 2010-03-09 Zenyth Operations Pty Ltd Receptor de hematopoyetina y secuencias geneticas que lo codifican.
US6911530B1 (en) 1995-10-23 2005-06-28 Amrad Operations, Pty., Ltd. Haemopoietin receptor and genetic sequences encoding same
FR2742156A1 (fr) 1995-12-06 1997-06-13 Sanofi Sa Polypeptide recepteur de l'il-13
BRPI9707379C8 (pt) 1996-02-09 2017-12-12 Abbott Biotech Ltd composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
US7078494B1 (en) 1996-03-01 2006-07-18 Genetics Institute, Llc Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US5710023A (en) 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
AU6450196A (en) 1996-06-12 1998-01-07 Human Genome Sciences, Inc. Hr-1 receptor
WO1998010638A1 (en) 1996-09-10 1998-03-19 Amrad Operations Pty. Ltd. Therapeutic molecules
DK0950067T3 (da) 1996-11-27 2007-12-27 Genentech Inc Affinitetsoprensning af polypeptid på protein A-matrix
GB9625899D0 (en) 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
US6743604B1 (en) 1996-12-13 2004-06-01 Smithkline Beecham Corporation Substances and their uses
KR20000070034A (ko) 1997-01-10 2000-11-25 아스트루 마이클 제이 항 cd40l 화합물로 신염성 루푸스를 치료하는 방법
BR9806793A (pt) 1997-01-22 2000-05-16 Univ Texas Processos e composições de fator tissular para coagulação e tratamento de tumores.
US6576232B1 (en) 1998-04-03 2003-06-10 The Penn State Research Foundation IL13 mutants
US6482403B1 (en) 1998-05-29 2002-11-19 Heska Corporation Caniney IL-13 immunoregulatory proteins and uses thereof
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
GB9820014D0 (en) 1998-09-14 1998-11-04 Cancer Res Campaign Tech Receptor antagonists and uses thereof
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
DE19848026A1 (de) 1998-10-17 2000-04-20 Bayer Ag Verfahren zur Herstellung von Bis(4-hydroxyaryl)alkanen
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
WO2000036103A1 (en) 1998-12-14 2000-06-22 Genetics Institute, Inc. Cytokine receptor chain
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
US6468528B1 (en) 1999-02-01 2002-10-22 Amgen Canada Inc. Materials and methods to inhibit Hodgkin and Reed Sternberg cell growth
WO2001034645A2 (en) 1999-11-11 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Mutated il-13 molecules and their uses
US20100041039A1 (en) 2000-01-15 2010-02-18 Synageva Biopharma Corp. Analysis of nucleic acid obtained from nucleated red blood cells
SI1257584T2 (sl) 2000-02-24 2013-07-31 Washington University St. Louis Humanizirana protitelesa, ki veĹľejo amiloidni peptid beta
JP3926153B2 (ja) 2000-03-03 2007-06-06 協和醗酵工業株式会社 遺伝子組換え抗体およびその抗体断片
CN1323812A (zh) 2000-05-16 2001-11-28 上海博德基因开发有限公司 一种新的多肽——人白细胞介素-13(il-13)受体11和编码这种多肽的多核苷酸
AU2002243443A1 (en) 2000-10-20 2002-07-24 Genetics Institute, Llc Method and composition for inhibition of tumor growth and enhancing an immune response
CA2424371A1 (en) 2000-10-20 2003-04-01 Chugai Seiyaku Kabushiki Kaisha Agonistic monoclonal antibody fragments
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US8372954B2 (en) 2000-12-22 2013-02-12 National Research Council Of Canada Phage display libraries of human VH fragments
EP1411983A4 (en) 2001-06-26 2006-06-21 Imclone Systems Inc BISPECIFIC ANTIBODIES BINDING TO VEGF RECEPTORS
US20030023555A1 (en) 2001-07-26 2003-01-30 Cashworks, Inc. Method and system for providing financial services
WO2003018635A1 (fr) 2001-08-31 2003-03-06 Kyowa Hakko Kogyo Co., Ltd. Anticorps greffes cdr humains et fragments de ces anticorps
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
WO2003035847A2 (en) 2001-10-26 2003-05-01 Centocor, Inc. Il-13 mutein proteins, antibodies, compositions, methods and uses
US20030235555A1 (en) 2002-04-05 2003-12-25 David Shealey Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
NZ532516A (en) 2001-11-07 2008-05-30 Cytos Biotechnology Ag Antigen arrays presenting IL-5, IL-13 or eotaxin for treatment of allergic eosinophilic diseases
WO2003066662A2 (en) 2002-02-05 2003-08-14 Genentech, Inc. Protein purification
US20040060102A1 (en) 2002-04-10 2004-04-01 Interspiro, Inc. Garments for biological, chemical and fire protection
AU2003265235A1 (en) 2002-04-26 2003-12-19 Genetech, Inc. Non-affinity purification of proteins
ES2365210T3 (es) 2002-06-14 2011-09-26 Government Of The United States Of America, As Represented By The Secretary, Department Of Health Procedimientos de tratamiento y prevención de colitis en la que se implican la il-13 y los linfocitos t citolíticos naturales.
EP1534323A2 (en) 2002-08-30 2005-06-01 Glaxo Group Limited Il-14 vaccine for the treatment of asthma and atopic disorders
WO2004019974A2 (en) 2002-08-30 2004-03-11 Glaxo Group Limited Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
DE10303664A1 (de) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
WO2004071408A2 (en) 2003-02-10 2004-08-26 Applied Molecular Evolution, Inc. Aβ BINDING MOLECULES
US7157276B2 (en) 2003-06-20 2007-01-02 Biogen Idec Inc. Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures
DK1639011T3 (da) 2003-06-30 2009-02-16 Domantis Ltd Pegylerede enkelt-domæne antistoffer (dAb)
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
EP3718564B1 (en) 2003-12-23 2023-10-11 Genentech, Inc. Novel anti-il 13 antibodies and uses thereof
AU2005205533B2 (en) 2004-01-07 2012-03-22 Novartis Vaccines And Diagnostics, Inc. M-CSF-specific monoclonal antibody and uses thereof
WO2005071410A1 (en) 2004-01-13 2005-08-04 Tanox, Inc. Detecting and quantifying host cell proteins in recombinant protein products
JP2008507253A (ja) 2004-02-06 2008-03-13 ナイモックス コーポレーション ヒト化抗体
ES2375627T3 (es) 2004-02-23 2012-03-02 Eli Lilly And Company Anticuerpos anti-abeta.
CA2565414A1 (en) 2004-05-04 2005-11-24 Novo Nordisk Health Care Ag O-linked glycoforms of polypeptides and method to manufacture them
US20070037966A1 (en) * 2004-05-04 2007-02-15 Novo Nordisk A/S Hydrophobic interaction chromatography purification of factor VII polypeptides
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
EP1805320B1 (en) 2004-10-22 2014-09-03 Amgen Inc. Methods for refolding of recombinant antibodies
ZA200706128B (en) 2004-12-24 2008-12-31 Commw Scient Ind Res Org Pesticide compositions and methods
RU2457214C2 (ru) 2005-03-11 2012-07-27 Вайет Способ хроматографии в режиме слабого распределения
NZ562949A (en) 2005-04-11 2009-05-31 Medarex Inc Protein purification using HCIC and ion exchange chromatography
EP1896504B1 (en) 2005-06-17 2012-11-21 Wyeth LLC Methods of purifying fc region containing antibodies
JP3982545B2 (ja) 2005-09-22 2007-09-26 ダイキン工業株式会社 空気調和装置
CA2623429C (en) 2005-09-30 2015-01-13 Medimmune Limited Interleukin-13 antibody composition
CA2625664C (en) 2005-10-21 2016-01-05 Novartis Ag Human antibodies against il13 and therapeutic uses
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
US7667557B2 (en) 2005-12-06 2010-02-23 Tdk Corporation Thin-film bandpass filter using inductor-capacitor resonators
ES2454253T3 (es) 2005-12-12 2014-04-10 Ac Immune S.A. Anticuerpos monoclonales específicos de beta A 1-42 con propiedades terapéuticas
AR057233A1 (es) 2005-12-12 2007-11-21 Hoffmann La Roche Glicosilacion en la region variable
PL1966244T3 (pl) 2005-12-30 2012-08-31 Merck Patent Gmbh Przeciwciała anty-il-6 zapobiegające wiązaniu il-6 skompleksowanego z il-6ralpha do gp130
US7563875B2 (en) 2006-03-20 2009-07-21 The United States of America as represented by the Sercretary of the Army Recombinant chimeric human anti-botulinum antibodies
CN102887955A (zh) * 2006-04-05 2013-01-23 艾博特生物技术有限公司 抗体纯化
WO2007124143A2 (en) 2006-04-21 2007-11-01 Wyeth Methods for high-throughput screening of cell lines
KR101605207B1 (ko) 2006-07-14 2016-03-22 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
ES2451266T3 (es) 2006-09-21 2014-03-26 Dsm Ip Assets B.V. Fosfolipasas, ácidos nucleicos que las codifican, y métodos para obtenerlas y usarlas
SI2074145T1 (sl) 2006-10-02 2017-12-29 Ac Immune S.A. Humanizirano protitelo proti amiloid beta
SI2069798T1 (sl) 2006-10-04 2014-07-31 Genentech, Inc. ELISA za VEGF
US8383350B1 (en) 2006-12-20 2013-02-26 Merck Sharp & Dohme Corp. Assay for detection of IL-10 antibodies
JP5419709B2 (ja) 2007-01-09 2014-02-19 ワイス・エルエルシー 抗il−13抗体製剤およびその使用
WO2008140455A1 (en) 2007-05-15 2008-11-20 Tanox, Inc. Treatment of radiation and chemo-therapy induced fibrosis using novel anti-il 13 monoclonal antibodies
PL2170389T3 (pl) 2007-06-12 2015-03-31 Ac Immune Sa Humanizowane przeciwciało przeciw amyloidowi beta
AR066987A1 (es) 2007-06-12 2009-09-23 Ac Immune Sa Anticuerpo monoclonal contra proteina beta-amiloide
US9433922B2 (en) 2007-08-14 2016-09-06 Emd Millipore Corporation Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same
CN105169388A (zh) 2007-10-05 2015-12-23 基因技术公司 人源化抗体
ES2445590T3 (es) 2007-10-05 2014-03-04 Genentech, Inc. Uso de anticuerpo anti-amiloide beta en enfermedades oculares
RU2571859C2 (ru) 2007-10-05 2015-12-20 Дженентек, Инк. Применение антитела против амилоида-бета при глазных заболеваниях
WO2009058769A1 (en) * 2007-10-30 2009-05-07 Schering Corporation Purification of antibodies containing hydrophobic variants
SG2014014138A (en) 2008-03-31 2014-07-30 Genentech Inc Compositions and methods for treating and diagnosing asthma
US8344115B2 (en) 2008-04-21 2013-01-01 Chan-Sui Pang, legal representative Immunoassay for specific determination of S-adenosylmethionine and analogs thereof in biological samples
SG190626A1 (en) 2008-05-05 2013-06-28 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
KR101667319B1 (ko) 2008-08-05 2016-10-18 도레이 카부시키가이샤 암의 치료 및 예방용 의약 조성물
US8790642B2 (en) * 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
GB0818674D0 (en) 2008-10-10 2008-11-19 Univ Bath Materials and methods for resolving polyhydric species by electrophoresis
CN102257007A (zh) 2008-10-20 2011-11-23 雅培制药有限公司 与il-18结合的抗体及其纯化方法
TW201024319A (en) 2008-10-20 2010-07-01 Abbott Lab Antibodies that bind to IL-12 and methods of purifying the same
JP5808249B2 (ja) 2008-10-20 2015-11-10 アッヴィ・インコーポレイテッド プロテインaアフィニティークロマトグラフィーを用いる抗体の単離および精製
SG10201702951RA (en) 2008-10-20 2017-06-29 Abbvie Inc Viral inactivation during purification of antibodies
CN101979404B (zh) 2008-12-09 2015-01-14 厦门大学 H5亚型禽流感病毒保守中和表位模拟肽及其用途
FR2944448B1 (fr) 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
WO2011010940A1 (en) 2009-07-19 2011-01-27 Serguei Zavtrak Solar electric power generator
ES2662529T3 (es) 2009-08-06 2018-04-06 F. Hoffmann-La Roche Ag Procedimiento para mejorar la eliminación de virus en la purificación de proteínas
US8709424B2 (en) 2009-09-03 2014-04-29 Merck Sharp & Dohme Corp. Anti-GITR antibodies
UA109884C2 (uk) 2009-10-16 2015-10-26 Поліпептид, що має активність ферменту фосфатидилінозитол-специфічної фосфоліпази с, нуклеїнова кислота, що його кодує, та спосіб його виробництва і застосування
WO2011050071A2 (en) 2009-10-20 2011-04-28 Abbott Laboratories Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
HUE038962T2 (hu) 2010-01-29 2018-12-28 Chugai Pharmaceutical Co Ltd DLL3-ellenes antitest
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
PH12018501083A1 (en) 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
ES2616010T3 (es) 2010-05-14 2017-06-09 The Board Of Trustees Of The Leland Stanford Junior University Anticuerpos monoclonales humanizados y quiméricos a CD47
CN103228673A (zh) 2010-05-17 2013-07-31 株式会社立富泰克 在体内具有抗肿瘤活性的抗人trop-2 抗体
SG10201710439UA (en) 2010-05-25 2018-01-30 Genentech Inc Methods of purifying polypeptides
EP2591005A2 (en) 2010-07-06 2013-05-15 Aveo Pharmaceuticals, Inc. Anti-ron antibodies
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
KR20130112879A (ko) 2010-09-29 2013-10-14 제넨테크, 인크. 항체 조성물 및 사용 방법
DK2646470T3 (en) * 2010-11-30 2017-05-08 Hoffmann La Roche ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH LOW AFFINITY AND ITS USE FOR TRANSPORTING THERAPEUTIC SCFV OVER THE BLOOD-BRAIN BARRIER
RU2737245C2 (ru) 2010-12-16 2020-11-26 Дженентек, Инк. Способы диагностики и лечения, связанные с ингибированием тн2
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
WO2013028330A2 (en) * 2011-08-19 2013-02-28 Emd Millipore Corporation Methods of reducing level of one of more impurities in a sample during protein purification
EP2773662A4 (en) * 2011-10-31 2015-07-01 Hoffmann La Roche ANTIBODY FORMULATIONS
EP2773439A4 (en) * 2011-10-31 2015-07-01 Merck Sharp & Dohme CHROMATOGRAPHY METHOD FOR RESOLVING HETEROGENIC ANTIBODY AGGREGATES
US20130129718A1 (en) * 2011-11-21 2013-05-23 Genentech, Inc. Purification of anti-c-met antibodies
JP6092892B2 (ja) 2011-12-15 2017-03-08 プレステージ バイオファーマ プライベート リミテッド 抗体の精製方法
WO2013120497A1 (en) * 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
EP2819697A4 (en) 2012-02-29 2016-03-09 Gilead Biologics Inc ANTIBODIES AGAINST METALLOPROTEINASE 9 OF MATRIX
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
IL244149B2 (en) * 2013-09-13 2025-09-01 Genentech Inc Methods and compositions containing purified recombinant polypeptides
CA3174012A1 (en) * 2013-09-13 2015-03-19 Genentech, Inc. Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography

Similar Documents

Publication Publication Date Title
JP2022036971A5 (enExample)
CA2921999C (en) Methods and compositions comprising an anti-il13 antibody and residual hamster phospholipase b-like 2
RU2016112549A (ru) Способ для повторного использования хроматографии
JP2008543881A5 (enExample)
JP2016539176A5 (enExample)
JP2016530533A5 (enExample)
US7662930B2 (en) Polishing steps used in multi-step protein purification processes
JP2014530848A (ja) 抗体を精製する方法
WO2018170488A1 (en) Method of purifying an antibody
CN107074906A (zh) 用于双特异性抗体的纯化平台
RU2014121886A (ru) Устройство для обработки курительного изделия и картридж для него
WO2017115773A1 (ja) Fc領域含有ポリペプチドの精製を効率化するための方法
JP2018510867A5 (enExample)
JP7566637B2 (ja) 混合物からポリペプチドを調製するための複数の疎水性相互作用クロマトグラフィーの使用
CN116063375A (zh) 在亲和层析中减少宿主细胞蛋白的方法
AU2025263876A1 (en) Methods for enhanced removal of impurities during protein a chromatography
JP2025090586A (ja) クロマトグラフィーの使用および再生のためのシステムおよび方法
JP2022530852A (ja) クロマトグラフィー樹脂の再生方法
KR20210045413A (ko) 다량체 단백질의 양 및 순도를 측정하기 위한 방법 및 크로마토그래피 시스템
Zhao et al. Applications of ion-exchange chromatography for the purification of antibodies
Vajda et al. Hydrophobic interaction chromatography for the purification of antibodies
CN114729002A (zh) 抗体色谱过程中的洗脱液收集
KR20220101168A (ko) 이온 교환 크로마토그래피 동안 항체의 수율을 증가시키는 방법
US20250188120A1 (en) Affinity chromatographic production of clinical human igg products
Zhang et al. Application of 4′-terpyridinylsulfanylethylamine resins for the purification of monoclonal antibodies by mixed-mode chromatography